Best Practices For Offering Value To Potential Partners – Highlights From LSX

At the 2024 LSX USA conference, panelists provided advice on how to approach companies in dealmaking and to make their value proposition fit with what the company is looking for.

Biz advice
Speakers at LSX USA 2024 offered best practices for dealmaking • Source: Shutterstock

With the flow of initial public offerings frustratingly sluggish and a tight financing environment, biopharma companies are looking for advice on other ways to bring in funding capital or explore business development options. In challenging times, experts agree it can be good to fall back on best practices.

Key Takeaways
  • Panelists at the recent LSX USA meeting offered advice to biotechs on how to approach partnering with deep-pocketed firms.

At the LSX World Congress USA, held 11-12 September in Boston, speakers from biopharma and other life sciences firms were...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.